Innovating Works

IRB

A stranger
Showing 1 to 20 of 35 results
T-RAFIC: Training network for tracking and controlling therapeutic immune cells in cancer Cancer immunotherapies have been established in a growing number of clinical indications and the pace of development is massively accelerat...
2024-07-16 - 2029-03-31 | financed
ISIDORe: Integrated Services for Infectious Disease Outbreak Research FONDAZIONE PER LISTITUTO DI RICERCA IN BIOMEDICINA participó en un HORIZON EUROPE HORIZON-INFRA-2021-EMERGENCY-02 The ISIDORe consortium, made of the capacities of European ESFRI infrastructures and coordinated networks, proposes to assemble the largest...
2022-02-09 - 2025-07-31 | financed
BRCA INSIGHTS: Understanding the functions of the BRCA protein complexes in DNA break repair and in replication str... FONDAZIONE PER LISTITUTO DI RICERCA IN BIOMEDICINA processed a H2020 ERC-2020-ADG BRCA1, BRCA2 and associated factors are frequently mutated in familial and sporadic cancers of the breast and ovary. The BRCA proteins have...
2021-06-03 - 2027-03-31 | financed
ATAC: Antibody therapy against coronavirus COVID 19 FONDAZIONE PER LISTITUTO DI RICERCA IN BIOMEDICINA participó en un H2020 H2020-SC1-PHE-CORONAVIRUS-2020 ATAC aims at developing passive immunotherapy against COVID-19. Human antibodies will be obtained from blood of CoV-recovered donors from Ch...
2020-04-06 - 2023-07-31 | financed
TIL-FIT: Increasing the fitness of tumor infiltrating T cells for cellular immunotherapy FONDAZIONE PER LISTITUTO DI RICERCA IN BIOMEDICINA processed a H2020 ERC-2018-STG Adoptive T cell therapies (ACTs) are emerging as a promising strategy to treat cancer. Tumor-infiltrating lymphocytes (TILs) are expanded ex...
2018-12-12 - 2023-12-31 | financed
RTCure: Rheuma Tolerance for Cure FONDAZIONE PER LISTITUTO DI RICERCA IN BIOMEDICINA participó en un H2020 H2020-JTI-IMI2-2016-09-two-stage In line with IMI2 goals for improved therapies and precision medicine, the aim of this proposal is to prevent and treat RA or its progressio...
2017-08-25 - 2023-08-31 | financed
TANTUMorNEUVACCINE: Neutrophil subtypes distinct cellular targets for therapeutic intervention FONDAZIONE PER LISTITUTO DI RICERCA IN BIOMEDICINA processed a H2020 H2020-MSCA-IF-2016 In cancer immunotherapy and vaccine field, considerable efforts have been invested to optimize the induction of effector T cells that, by re...
2017-04-04 - 2020-09-30 | financed
ZIKAlliance: A global alliance for Zika virus control and prevention FONDAZIONE PER LISTITUTO DI RICERCA IN BIOMEDICINA participó en un H2020 H2020-SC1-2016-2017 "ZIKAlliance is a multidisciplinary project with a global ""One Health"" approach, built: on a multi-centric network of clinical cohorts in...
2016-12-13 - 2021-09-30 | financed
HRMECH: Nucleases in homologous recombination from basic principles to genome editing FONDAZIONE PER LISTITUTO DI RICERCA IN BIOMEDICINA processed a H2020 ERC-2015-CoG Homologous recombination plays a crucial role to repair DNA strand breaks that may occur spontaneously upon replication fork collapse, durin...
2016-08-08 - 2022-03-31 | financed
EHVA: European HIV Vaccine Alliance EHVA a EU platform for the discovery and evaluation of novel prophy... FONDAZIONE PER LISTITUTO DI RICERCA IN BIOMEDICINA participó en un H2020 H2020-PHC-2014-2015 Many HIV vaccine concepts and several efficacy trials have been conducted in the prophylactic and therapeutic fields with limited success. T...
2015-12-17 - 2023-12-31 | financed
BROADimmune: Structural genetic and functional analyses of broadly neutralizing antibodies against human pathoge... FONDAZIONE PER LISTITUTO DI RICERCA IN BIOMEDICINA processed a H2020 ERC-2014-ADG The overall goal of this project is to understand the molecular mechanisms that lead to the generation of potent and broadly neutralizing an...
2015-09-30 - 2020-09-30 | financed
ABIRISK: Anti-Biopharmaceutical Immunization:Prediction and analysis of clinical relevance to minimize the ri... FONDAZIONE PER LISTITUTO DI RICERCA IN BIOMEDICINA participó en un FP6 The ABIRISK project provides an integrated approach to the study of immunization against biopharmaceuticals, bringing together a unique pane...
2012-03-01 - 2018-02-28 | financed
LINFOEPAB: CD4 T AND B LYMPHOCYTES IN HEPATITIS B PATIENTS ROLE IN ACUTE AND CHRONIC INFECTION FONDAZIONE PER LISTITUTO DI RICERCA IN BIOMEDICINA processed a FP7 "Hepatitis B virus (HBV), an hepatotropic non-cytopathic DNA virus, still represents a global health problem, with million of deaths for yea...
financed
IRINVAC: IMMUNE RESPONSES TO INFLUENZA VACCINE FONDAZIONE PER LISTITUTO DI RICERCA IN BIOMEDICINA processed a FP7 Influenza virus continues to represent a major global health problem and the recent pandemic caused by a H1N1 strain of influenza A (swine f...
financed
MD-THIV: Migration and Differentiation of Th17 Cells in HIV SIV Infection FONDAZIONE PER LISTITUTO DI RICERCA IN BIOMEDICINA processed a FP7 More than 25 years after the discovery of human immunodeficiency virus (HIV) as the causative agent of AIDS, the mechanisms governing pathog...
financed
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.